Jennifer Kelly Shepphird

News

NRAS mutations predict immunotherapy outcomes in melanoma patients

Author:: Jennifer Kelly Shepphird

Publish date: March 3, 2015

Key clinical point: Patients with advanced melanoma and mutations in the NRAS gene had better responses to immunotherapy than did those without NRA...

News

Liquid biopsy consistent with tumor biopsy for NSCLC

Author:: Jennifer Kelly Shepphird

Publish date: February 26, 2015

Key clinical point: The EGFR mutation L858R detected in both tissue and cfDNA predicted shorter OS and PFS than did the exon 19 deletion. Major fi...

News

Oral Bisphosphonates Linked with Lower Risk of Endometrial Cancer

Author:: Jennifer Kelly Shepphird

Publish date: February 23, 2015

Key clinical point: Oral bisphosphonate use was modestly associated with reduced risk of endometrial cancer. Major finding: Risk of endometrial ca...

News

Oral bisphosphonates linked with lower risk of endometrial cancer

Author:: Jennifer Kelly Shepphird

Publish date: February 23, 2015

Key clinical point: Oral bisphosphonate use was modestly associated with reduced risk of endometrial cancer. Major finding: Risk of endometrial ca...

News

Bevacizumab fails to improve outcomes for metastatic uterine leiomyosarcoma

Author:: Jennifer Kelly Shepphird

Publish date: February 23, 2015

Key clinical point: Bevacizumab added to gemcitabine-docetaxel did not improve outcomes in patients with uterine leiomyosarcoma. Major finding: Me...

News

Uterine cancer low in myomectomy with power morcellation

Author:: Jennifer Kelly Shepphird

Publish date: February 19, 2015

Key clinical point: Among women who underwent myomectomy, the prevalence of cancers was low but increased with age. Major finding: Rates of uterin...

News

Bevacizumab plus ET failed to improve PFS in HER2-negative, HR-positive BC

Author:: Jennifer Kelly Shepphird

Publish date: February 17, 2015

Key clinical point: In women with HER2-negative, hormone receptor–positive breast cancer, the addition of bevacizumab to endocrine therapy d...

News

Time and money spent locating unknown primary tumor site might be better spent on genomic analyses

Author:: Jennifer Kelly Shepphird

Publish date: February 14, 2015

Key clinical point: The resources and time spent to locate the primary tumor site in patients with metastatic unknown primary cancer might be bett...

News

Overall survival plateaus at 3 years for ipilimumab-treated melanoma patients

Author:: Jennifer Kelly Shepphird

Publish date: February 9, 2015

Key clinical point: Ipilimumab-treated advanced melanoma patients alive at 3 years tend to have good long-term outcomes. Major finding: Around yea...